about
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer.Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status.Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis.Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer.Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study.No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide.PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.The third line of treatment for metastatic prostate cancer patients: Option or strategy?Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer.An exceptional overall survival using bevacizumab beyond progression in a patient with non-small cell lung cancer.Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study.Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer.Is there still a place for docetaxel rechallenge in prostate cancer?Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer.Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.Targeted Therapies for Prostate CancerTime of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)Tumor fraction in cell-free DNA as a biomarker in prostate cancerLow-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate CancerTolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC)Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinomaGemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II studySequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experienceHow to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissueEfficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of ChemotherapyImpact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry
P50
Q33374104-B3B86154-14F5-4B42-93D1-85C80D3EF23CQ33421361-FB86DEA0-675D-48E1-80D7-F6BBF6700B17Q33421476-945E7927-B4DF-4A88-83AF-B74F119F4424Q33424849-3AC340EF-C9AB-4D33-8713-25E42EE0E938Q33431544-F090B0C5-A393-4D34-BC70-20C07330CAB1Q36211461-9C16B451-67F7-49D7-BE8F-82FD9EB3E60DQ37321114-A7625507-DFB4-4990-A40D-A30F455F678EQ38241095-0057F56C-5B1A-484C-B3C5-BE41EA170683Q38246587-990EDD49-3574-4DDC-97C3-C91BA938EB37Q38519778-FDC9335B-CB46-4AB3-B5A3-10E8292A6F13Q38530028-85F45EBB-C4F4-486D-B034-99AD635FEB73Q38969949-BDE5FFAA-075D-4EF6-A776-D6A2AC7E5AD8Q40487286-54E36781-156E-4240-B133-49F06B5F0655Q40859512-30B8FD65-AEE0-40C7-9327-6B413E1B2527Q41686856-D6F87EF1-F562-438B-B532-BE610824D7E8Q42015004-E7254D60-3647-42B3-A677-359C57E499E1Q42096514-715B9DA9-7EF5-4E6C-B27C-5B449E90B531Q45389025-B9867387-D694-45C7-8771-AE3E3D091875Q50055627-F45B61C4-2B84-4F88-854F-B3A12E2B29F3Q50963866-2B5BC768-05B7-4901-ACB8-2EEA18A4BCC7Q53737270-0C39DC35-70AC-4A09-AACE-7F75B5555D02Q57125162-3E5C0F0C-3592-4A06-8CF0-7F2FD1EBB714Q57165997-92F4B648-CC3D-46C6-845B-0AADB1D82AB3Q58617288-18A112DD-E4B8-4AAA-B447-4A47DD43CE73Q59485403-22FA8DE5-FA3C-4D7C-BB7F-F6816F330174Q85249493-8A110ADF-D0F4-4EEC-97B5-729B8D80CCEAQ86030932-DAC2532E-58DF-4C6E-948D-2852F792C345Q86592713-B4E1BFA8-6A40-432A-A3B8-D8690009CC4AQ86875663-44B9CB16-A04C-416B-9DF0-305726508F28Q87977152-9B160C21-D709-43FE-AA51-5FF798E9076DQ88083622-CC1C350B-28E6-4295-8B28-2DA4A8AADD05Q91045350-96E7112A-AB75-4503-9EAC-AE9EA8D3B05F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
E Francini
@ast
E Francini
@en
E Francini
@es
E Francini
@nl
type
label
E Francini
@ast
E Francini
@en
E Francini
@es
E Francini
@nl
prefLabel
E Francini
@ast
E Francini
@en
E Francini
@es
E Francini
@nl
P106
P1153
15831732700
P31
P496
0000-0003-4270-7023